However, our current study demonstrates that PGP degradation by LTA4H is already aberrant in CC-CF children, potentially owing to degradation of LTA4H by neutrophil elastase, and thus it is feasible that any potential adverse effects of Acebilustat in inhibiting PGP degradation by LTA4H would be negligible in CF. The gene discussed is LTA4H; the disease is cystic fibrosis.